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Abstract
Background: Immunization against amyloid-b (Ab), the peptide that accumulates in the form of senile plaques
and in the cerebrovasculature in Alzheimer’s disease (AD), causes a dramatic immune response that prevents
plaque formation and clears accumulated Ab in transgenic mice. In a clinical trial of Ab immunization, some
patients developed meningoencephalitis and hemorrhages. Neuropathological investigations of patients who died
after the trial showed clearance of amyloid pathology, but also a powerful immune response involving activated T
cells probably underlying the negative effects of the immunization.
Results: To define the impact of T cells on this inflammatory response we used passive immunization and
adoptive transfer to separate the effect of IgG and T cell mediated effects on microhemorrhage in APPPS1
transgenic mice. Neither anti Ab IgG nor adoptively transferred T cells, alone, led to increased cerebrovascular
damage. However, the combination of adoptively transferred T cells and passive immunization led to massive
cerebrovascular bleeding that ranged from multiple microhemorrhages in the parenchyma to large hematomas.
Conclusions: Our results indicate that vaccination can lead to Ab and T cell induced cerebral micro-hemorrhages
and acute hematomas, which are greatly exacerbated by T cell mediated activity.
Background
Immunotherapeutic approaches to treat neurodegenera-
tive diseases have gained prominence in the last few
years, particularly in the field of Alzheimer’sd i s e a s e
(AD) research. AD and mouse models of amyloid
pathology both have an innate immune response to
amyloid-b deposition, which is probably beneficial [1].
The devastating mental effects of Alzheimer’sd i s e a s e
are caused by pathological changes in the brain includ-
ing the accumulation of amyloid-b peptide (Ab)e i t h e r
in the parenchyma in the form of senile plaques or in
the cerebrovasculature (CAA-cerebral amyloid angiopa-
thy). Mice that have been genetically altered so that they
have quantities of Ab in their brains have plaque pathol-
ogy similar to that seen in Alzheimer’s patients [2-4].
Studies of immunizing these APP transgenic mice with
the Ab peptide led to the exciting discovery that the
immune system can prevent plaque formation and even
reverse some of the damage by producing antibodies to
Ab [5]. Subsequent experiments confirmed the neuro-
pathological benefits of immunization and showed that
it also benefits the behavioral symptoms associated with
amyloid deposition [6-10]. Furthermore the clearance of
plaques can lead to normalization of the neuritic pro-
cesses and dystrophies surrounding plaques, suggesting
an astonishing degree of plasticity in the adult brain,
and potential for recovery [11-13].
B a s e do nt h i se v i d e n c ei nA P Pt r a n s g e n i cm i c et h a t
immunization can reduce Alzheimer’s pathology, a clini-
cal trial was run in which patients with Alzheimer’sd i s -
ease were immunized against Ab.AP h a s eIs t u d yi n
AD patients demonstrated good safety and tolerability of
multiple injections of aggregated Ab42 (AN 1792) [14].
Clinical evaluation showed slower rates of decline of
mental function in some of the treated patients [15], but
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most minimal [14,16]. A postmortem examination of
this Phase I immunization trial showed evidence of a
significant reduction in brain amyloid plaques, together
with increased blood anti-Ab antibody levels [17]. How-
ever, the Phase II trial was discontinued after 6% of the
participants developed meningoencephalitis, a life-threa-
tening inflammatory reaction [18]. Two patients died
and examination of their brains showed decreased
amounts of plaques when compared to nonimmunized
patients, but there was also evidence of inflammatory
infiltrates that involved activated T cells [16,19].
To circumvent these adverse effects, another Phase 2
trial of passive immunization with the N-terminal
monoclonal antibody Bapineuzumab was carried out.
Although Bapineuzumab did not offer a clinical benefit,
a subgroup of ApoE4 non-carriers performed better on
cognitive measures and experienced fewer adverse
effects. The most concerning adverse effect of this study
was the development of vasogenic oedema, which
occurred in 10% of the patients preferentially ApoE4
carriers treated with higher doses of ≥ 1 mg/kg Bapineu-
zumab [20,21]. In a smaller Phase 2 trial, PET imaging
with the amyloid tracer Pittsburgh Compound B showed
a reduction in brain amyloid load in AD patients treated
with Bapineuzumab. In agreement with the above men-
tioned study, 2 patients receiving the higher dose of
2 mg/kg developed cerebral vasogenic oedema [22].
Understanding the factors that are required to induce
Ab encephalitis and microhemorrhages is crucial for the
development of Ab vaccination approaches. In order to
address the important clinical question of why immuni-
zation against Ab causes a harmful inflammatory reac-
tion in the brain we monitored the T cell response to
Ab immunization in APPPS1 transgenic mice. Trans-
genic mice expressing green fluorescent protein (GFP)
in specific subpopulations of T cells [23] were immu-
nized with Ab42 followed by adoptive transfer of these
fluorescently labeled T cells into APPPS1 transgenic
mice. With our experimental setting we observed micro-
hemorrhages in the host mice after application of anti
Ab antibodies, similar to those observed in human
patients; in at least one patient, frank hemorrhage was
also reported [19], similar to the results in this animal
model. These results suggest that Ab activated T cells
would be a possible marker to screen for in AD patients
before they undergo passive immunization.
Results
Generation of Ab specific T cells ex vivo
Thy1.1+ congenic mice were immunized subcutaneously
with either Ab peptide plus complete Freund`s adjuvant
(CFA) or with CFA alone and boosted after 14 days. At
day 21 total splenocytes were re-stimulated ex vivo with
Ab peptide and the T cells were analyzed for their
degree of proliferation with the fluorescent dye 5,6-car-
boxylfluorescein diacetate succinimidyl ester (CFSE dilu-
tion) and production of effector cytokines (Figure 1). As
expected, T cells from mice previously immunized with
Ab peptide exhibited a higher proliferative capacity
(Figure 1B) and produced higher levels of effector cyto-
k i n e ss u c ha sI L - 2a n dI F N g as compared to T cells
from control mice (Figure 1C,D). These results indicate
that Ab immunization was effective for priming and
expanding Ab-specific effector T cells.
Development of acute hematomas
With age, APPPS1 transgenic mice develop dense core
Ab deposits in the parenchyma in forms of plaques and,
later and in small amounts, around blood vessels (CAA).
In order to investigate the T cell inflammatory response,
developed as a consequence of active immunization in
human Alzheimer’s patients, we immunized T-GFP
mice with Ab42 followed by adoptive transfer of these
fluorescently labeled T cells into mice that are trans-
genic for human APP. One week after the adoptive
transfer, we performed a cranial window surgery with
dura removal and antibody application of either anti-
body 10D5 against Ab or control antibody 16D5 against
human tau (Figure 2A). In vivo multiphoton microscopy
for visualization and tracking of T cells in the brain of
APPPS1 transgenic mice did not detect any transferred
T cells during 1 hour in vivo imaging sessions (Addi-
tional File 1, Figure S1 A,B) although green T cells were
readily found at post mortem examination, most promi-
nently in the spleens of the mice (Additional File 1,
Figure S1 D).
Instead, after adoptive transfer of Ab activated T
cells we observed bleeding and hemorrhage in APPPS1
transgenic mice after T cell transfer and immunization
procedure (Figure 2B) similar in many respects to
those reported in human patients undergoing active
immunization. All APPPS1 transgenic animals that
received both T cell transfer and Ab antibody treat-
ment developed massive bleeding 3-4 days after the
surgical procedure and passive immunization in con-
trast to the wildtype animals. In control experiments
where either the control antibody 16B5 or no antibody
was administered or where only the antibody 10D5
was applied but no GFP positive T cells transferred, no
sign of bleeding was evident in the mice, suggesting
that the bleeding was probably due to a combination
of both Ab-specific antibody application and adoptive
T cell transfer.
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Page 2 of 10Figure 1 Generation of Ab-specific effector T cells.( A) Thy1.1+ C57Bl/6 mice were immunized subcutaneously with Ab peptide plus CFA or
with CFA alone (control mice). 14 days later, the mice were boosted with either Ab peptide plus IFA or IFA alone. 7 days later the mice were
euthanized and splenocytes were isolated from either Ab-immunized or control mice. (B-D) In order to assess Ab-specific T cell responses, CFSE-
labeled splenocytes were incubated ex vivo with Ab peptide and 4 days later were analyzed for their CFSE dilution (as a readout of T- cell
proliferation) (B) and production of effector cytokines by intracellular staining (C and D). Flow cytometry analyses were restricted to viable cells
and gated on T cells. T cells from mice immunized with Ab peptide exhibited a higher degree of proliferation (CFSE dilution) and produced
higher levels of effector cytokines when restimulated ex vivo with Ab peptide as compared to T cells from control mice.
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microhemorrhages after passive immunization in APPPS1
transgenic
Due to the massive bleeding, it was not possible to
reimage these animals and therefore the brains were
analyzed postmortem. It has been previously reported
that APP transgenic mice that received passive anti-Ab
immunotherapy develop CAA-associated microhemor-
rhages [24-26]. To determine whether transferred T
cells induced additional microhemorrhages after passive
immunization we carried out microhemorrhage analysis.
Old hemorrhages were studied using Prussian Blue
stain, which identifies residual hemosiderin. Acute
bleeding was assessed in H&E-stained sections. We
detected hemosiderin deposits in the cortex that were
localized in the cytoplasma of microglial cells in all
treated mice (Figure 3A-H). Strikingly, we found a dra-
matic fourfold increase in the number of microhemor-
rhages specifically in the cortex of APPPS1 transgenic
mice that received T cells and were passively immu-
nized. In addition, it is important to note that these
old microhemorrhages appeared to be also larger in
size than the rare microhemorrhages seen in animals
that did not receive T cells (Figure 3G,H,I). Similar
Figure 2 Schematic illustration of the experimental in vivo approach and the incidence of bleedings in APPPS1 transgenic mice.( A)
We immunized T-GFP mice with Ab42 and adoptively transferred these isolated T cells via the tail vein into transgenic or control mice. After a
recovery period of one week, a cranial window surgery with dura removal and antibody application of either antibody 10D5 against Ab or
control antibody 16D5 against human tau was performed. Brains were analyzed postmortem 3 to 4 days after passive immunization. (B)I n
contrast to wildtype mice passively immunized (left image) or APPPS1 transgenic mice immunized with a control antibody against human tau
(right image) transgenic mice immunized with anti Ab antibody developed acute hematomas on both hemispheres as indicated by black arrows
(image in the middle).
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analyzed with an approximately threefold increase in
microhemorrhage frequency as well as increase in
hemorrhage size (Figure 4).
T cell related microhemorrhages segregated from CAA
The distribution of the microhemorrhages in the cortex
of 10D5-treated mice was consistent with the distribu-
tion of CAA reported in this APPPS1 transgenic mouse
model [27]. To determine if microhemorrhages were
directly associated with CAA, we additionally stained
the sections for deposited amyloid by Thioflavine-S. In
agreement with an earlier study these APPPS1 trans-
genic mice developed only very limited amount of CAA
[27]. We did not find CAA-associated microhemor-
rhages but instead we observed microhemorrhages that
were not closely related to CAA (Additional File 1,
Figure S2 A-H).
To investigate whether these induced microhemor-
rhages may have been caused by the infiltration of
Figure 3 Increase in number of old microhemorrhages following passive immunization.( A-H) Sections are stained for hemosiderin
(extravenous iron in blue) with Prussian Blue and cells counterstained with nuclear fast red (A-G) Panels show the cortex of either a wildtype
control mouse (A), APPPS1 transgenic mouse treated with control antibody 16B5 (C) or 10D5 treated APPPS1 mouse lacking the transferred T
cells (E). The arrow in (G) denotes a massive clustering of hemosiderin positive microglia in T cell transferred mice following IgG aAb treatment.
(B-H) Panels are a higher magnification of the cortical area shown in (A-G).( I) Quantification of Prussian Blue staining illustrated as the number
of positive profiles per brain. Note the fourfold increase in hemorrhage frequency in APPPS1 transgenic mice which received T cells and were
passively immunized. Scale bars, 100 μm (A,C,E,G), 50 μm (B,D,F,H).
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brain sections with anti-GFP and anti-CD3 antibodies to
identify all transferred T cells in the parenchyma. We
observed a few clusters of T cells positive for CD3
(Figure 5A,B) as well as for GFP (Figure 5C,D) primarily
located within the acute hemorrhages, indicating that
the adoptively transferred T cells indeed entered the
CNS and secondly caused massive bleeding. Notably,
these few small groups of CD3 positive cells were not
associated with plaques. Likewise, we did not observe
any CD3 positive cell clustering around the vasculature,
which would have been expected to occur with an ence-
phalitogenic response.
Discussion
To continue developing clinical AD therapies based on
Ab immunization, such strategies will clearly need to
avoid meningoencephalitic reactions to Ab immuniza-
tions previously observed in humans [1,18]. Postmortem
analysis suggested that inflammatory infiltrates found in
Figure 4 Increase in number of acute hematomas following passive immunization.( A-H) Evidence of acute hematomas was assessed in
H&E-stained sections confirming the occurrence of acute bleedings in all animals used in this study. (G) The black arrow indicates a significant
hemorrhage in T cell transferred mice following IgG aAb treatment. (B-H) Panels are a higher magnification of the cortical area shown in (A-G).
(I) Quantification of acute hemorrhages in the different groups revealed a threefold increase in APPPS1 transgenic mice that have received Ab
primed T cells and were passively immunized. Scale bars, 100 μm (A,C,E,G), 50 μm (B,D,F,H).
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Page 6 of 10the AD brain involved activated T cells [16,19]. Here we
investigated in an animal model the impact of T cells
(previously exposed to the antigen) on the inflammatory
events that occur during Ab immunization by transfer-
ring activated T cells of TGFP mice into APPPS1 trans-
g e n i cm i c ef o l l o w i n ga n t iA b antibody application in
order to separate the effect of IgG and T cell mediated
effects. The infusion of Ab specific T cells (using a pro-
tocol enriching for Th2 T cells, in comparison to our
protocol) into APPPS1 transgenic mice has previously
been shown to have beneficial effects such as reversing
cognitive impairment and synaptic loss without infiltrat-
ing the CNS [28,29]. Extending these experimental pro-
cedures we performed passive immunization of the
recipient APPPS1 mice and found massive bleeding and
microhemorrhages, delayed several days after the infu-
sion of activated T cells, indicating that the combined
effect of activated T cells and passive immunization pro-
cedures can be devastating. Whether transferred T cells
crossed the blood brain barrier and were attracted by
senile plaques or CAA could not be inferred from these
experiments, because massive bleeding started 3 days
after surgery and made live imaging with 2-Photon
microscopy impossible. We therefore were restricted
methodologically to postmortem brain analysis in
addressing T cell-mediated inflammatory events that
occur during amyloid-b (Ab) immunization. In this
study, we did not observe the previously reported corre-
lation between microhemorrhages and CAA in APP
transgenic mice [24-26,30,31]. This might be due to the
fact that the mouse model we used only develops a lim-
ited amount of CAA in general [27].
T cell trafficking into the CNS is thought to occur
when activated T cells cross the blood brain barrier.
One can think of 2 possible scenarios: T cell mediated
neuropathological events may occur indirectly as a result
of bystander damage by co-infiltrating T cells with irre-
levant antigen specificities or may be mediated directly
by antigen specific T cells. Our data speak for the latter
insofar as only transferred T cells previously stimulated
by Ab42 (in combination with antibody treatment of the
recipient mouse) induced frank bleeding or microhe-
morrhages. We indeed observed cells positive for GFP
and CD3 located within the bleeding, showing that
these antigen specific T cells crossed the blood brain
barrier and likely participate to the undesirable side
effect of Ab immunization. This result is in accord with
a study demonstrating that bystander T cells can only
traffic to the CNS with very limited efficiency and have
only small contribution to neuropathological changes
[32].
The fact that only the combination of both T cells and
Ab antibodies induced microhemorrhage indicates that
reactive T cells could be a potential biomarker to screen
for higher risk AD patients considering passive immuni-
zation against Ab. The goal of safer immunotherapy
approaches is already under development, although
vasogenic edema has been observed even with only pas-
sive immunization, and current active anti-Ab vaccine
designs do not include a self T cell epitope.
Conclusions
In sum, our results provide two key implications: first,
in this model it appears that T cells participate in the
pathophysiological process associated with anti-Ab
immune mediated microhemorrhage. Second, although
immunization-associated microhemorrhage has been
reported in a large number of mouse models
[24-26,30,33], the microhemorrhages are frequently
inconsistent and scattered; because the current data sug-
gest uniform readily detected microhemorrhage within a
small time window of antibody therapy, the current pro-
tocol may provide a more systematic method to test var-
ious anti-Ab therapeutics for hemorrhagic effects of
immunotherapy.
Methods
Animals
APPswe/PS1d9 transgenic mice aged 7-11 months and
control littermates the same age were used in this study
(obtained from Jackson lab, Bar Harbor, Maine) [4].
APPswe/PS1d9 transgenic mice start to develop plaques
and CAA in the neocortex between 5 and 7 months of
age. TGFP transgenic mice that express green
Figure 5 GFP and CD3 positive T cells infiltrate the CNS and
are mainly located within the hemorrhages. (A,B) CD3
immunostaining of the cortex revealed a cluster of sporadic T cells
throughout a significant hemorrhage. (C,D) GFP immunostaining of
an adjacent section of the same area confirmed the occurrence of
Ab primed adoptively transferred T cells restricted to this
hematoma. Scale bars, 100 μm (A,B), 20 μm (C,D).
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ine CD4 promoter in CD4
+ and CD8
+ have been used
as donor for the adoptive transfer experiments [34]
(obtained from Uli von Andrian). All animal work was
conducted with approved protocol from the Massachu-
setts General Hospital Animal Care and Use Committee
and in compliance with NIH guidelines for the use of
experimental animals.
T cell isolation and adoptive T cell transfer
Thy1.1+ C57BL/6 mice or DPE-T-GFP mice (in which
all T cells express GFP) [34] were immunized subcuta-
neously with Ab42 peptide (2 mg/mouse) in complete
Freund’s adjuvant (CFA, Sigma-Aldrich, Saint Louis,
MO). The concentration of mycobacteria in the CFA
formulation was 0,1%. 14 days later, the mice were
boosted with 2 mg Ab peptide in incomplete Freund’s
adjuvant (IFA). Control mice were immunized and
boosted only with CFA and IFA, respectively. 1 week
later (day 21) the mice were euthanized and the spleno-
cytes were labeled with 5 μM carboxyfluorescein succi-
nimidyl ester (CFSE) and cultured ex vivo with or
without 10 μMA b peptide. T cells were analyzed by
flow cytometry at day 4 for their CFSE dilution (T cell
proliferation) and cytokine production (IL-2 and IFNg)
by intracellular staining. In order to detect intracellular
cytokines, T cells were additionally re-stimulated for
4 hours with PMA plus ionomycin in the presence of
brefeldin-A, as described [35]. T cells of immunized
DPE-T-GFP mice (140 × 10
7 cells in 0.3 ml total volume)
were adoptively transferred via the tail vein into recipient
APPPS1 transgenic or non transgenic control mice.
Surgical procedure
One week after the adoptive transfer of T cells, mice
received an intraperitoneal injection of methoxy-O4
(5 mg/kg) a fluorescent compound that crosses the
blood-brain barrier and binds to amyloid plaques and
CAA [36]. The following day a cranial window surgery
was done under avertin anesthesia (1.3% 2,2,2-tribro-
methanol, 0.8%tert-pentylalcohol; 250 mg/kg) by instal-
ling a glass window 6 mm in diameter on top of the
brain [36-38]. The dura was carefully retracted to the
midline with fine forceps and a single antibody applica-
tion of 20 μl of 1 mg/ml of either an antibody against
the N-terminal of Ab (10D5, IgG1) or a control anti-
body directed to an unrelated epitope (anti-human tau
16B5) was then applied to the surface of the brain
before attachment the glass coverslip with dental
cement. Texas Red dextran (70,000 Daltons molecular
weight, 12.5 mg/ml in sterile phosphate-buffered saline,
Molecular probes, Eugene, OR) was injected into the lat-
eral tail vein to provide an angiogram.
Imaging methods
Mice were imaged immediately after surgery while still
under anesthesia, and then allowed to recover. In vivo
imaging of amyloid pathology and blood vessels in the liv-
ing mouse brain was performed on a Bio-Rad 1024ES
multiphoton microscope (Bio-Rad Laboratories, Hercules,
CA), mounted on an Olympus BX50WI upright micro-
scope (Olympus Optical, Tokyo, Japan). A wax ring was
placed around the coverslip of the cortical window and
filled with distilled water to create a well for an Olympus
20x dipping objective (numerical aperture 0.95). A mode-
locked Ti:Saphire laser (MaiTai, Spectra-Physics, Moun-
tain View, CA) generated two-photon fluorescence with
800 nm excitation, and detectors containing three photo-
multiplier tubes (Hamamatsu Photonics, Bridgewater, NJ)
collected emitted light in the range of 380-480, 500-540,
and 560-650 nm. During each imaging session, images at
low resolution (615 μm × 615 μm×5μm sections; 10-20
sections per stack) were captured to provide an overview
of the area, followed by images with high resolution
(approximately 150 μm × 150 μm×1μm sections;
15-50 sections per stack) to zoom in on a specific area. At
the end of each imaging sessions, mice were allowed
to recover on a heating pad and placed singly in their
home cage.
Postmortem analysis
3 to 4 days after 10D5 antibody application for passive
immunization, the mice developed hematomas and
therefore had to be sacrificed immediately. Mice were
euthanized by CO2 inhalation and the brains and
spleens were immersion-fixed for 2 d in 4% paraformal-
dehyde, and the brains then embedded in paraffin. Cor-
onal serial sections of 8 μm thickness were cut with a
microtome throughout the brain. Hematoxylin and
eosin (H&E) and Thioflavine-S staining were done
according to standard protocols [39] and Prussian Blue
staining was performed as previously described [39,40].
The Prussian Blue method was used to visualize old
hemorrhages by microglia that have been engulfed ferric
iron-containing hemosiderin from red blood cells. To
test if microhemorrhages were associated with CAA,
some sections were costained with Thioflavine-S. Prus-
sian Blue stain was imaged first because of extremely
rapid dissolution of the blue precipitate after UV excita-
tion required for Thioflavine-S imaging. Immunohisto-
chemistry on paraffin sections was performed by using
the avidin-biotin-peroxidase complex method (Vector
Laboratories, Burlingame, CA) with diaminobenzidine as
chromogen. The following primary antibodies were
used: polyclonal antibody against GFP (Abcam, Cam-
bridge, MA) and the rat monoclonal antibody against
C D 3( A b DS e r o t e c ,R a l e i g h ,N C ) .B o t hs t a i n i n g sw e r e
done with heat-induced antigen retrieval as recom-
mended by the antibody providers (citrate buffer, pH 6.0
at 95°C for 20 min). Micrographs of immunostaining
were obtained on an upright Olympus Optical BX51
fluorescence microscope with an Olympus Optical DP70
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(Adobe Systems, San Jose, CA).
Quantification
Cerebral hemorrhage is accompanied by a delayed
appearance of hemosiderin-positive microglia [41]. Prus-
sian blue stained clusters of hemosiderin staining was
quantified on sets of systematically sampled sections
(every 10
th section throughout the cortex). An additional
set of every 10
th section was stained for H&E and
screened for acute intraparenchymal bleedings visible as
large accumulation of erythrocytes in the parenchyma.
Statistical analysis
All quantitative analysis was performed without knowl-
edge of the treatment group. Two independent experi-
menters counted the microhemorrhages, and an average
score was used. All statistical analyses were done with
the StatView program (SAS Institute, Inc, Cary, NC).
Data were expressed as mean ± standard deviation from
the mean. Significance levels were set at p < 0.05.
Additional material
Additional file 1: Figure S1: GFP positive T cells could not be
detected in the brain via multiphoton imaging. (A,B) Three-colour in
vivo multiphoton images showing senile plaques in blue along with
blood vessels in red from the living brain of an APPPS1 transgenic
mouse that previously received Ab specific GFP positive T cells. No
evidence of GFP positive T cells was observed. (C) In contrast, many
green T cells could be detected in the spleen but were missing in the
spleen of a control mouse which did not receive GFP positive T cells (D).
Scale bars, 100 μm (A,B), 100 μm (C,D). Figure S2: Microhemorrhages
are not related to CAA (A,B) Prussian Blue stained sections show
clustering of hemosiderin positive microglia in the cortex (black arrow).
(C,D) The white arrowhead points towards CAA located away from the
bleeding in Thioflavine-S stained consecutive sections. (E,F) Another
example of a Prussian Blue positive microhemorrhage without any
Thioflavine-S positive CAA in its vicinity (G,H). Scale bars, 400 μm (A,B),
100 μm (C,D).
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